|
1
|
World Health Organization (WHO): Cancer.
WHO; Geneva: 2022, https://www.who.int/news-room/fact-sheets/detail/cancer.
Accessed February 3, 2022.
|
|
2
|
Philips CA, Rajesh S, Nair DC, Ahamed R,
Abduljaleel JK and Augustine P: Hepatocellular carcinoma in 2021:
An exhaustive update. Cureus. 13:e192742021.PubMed/NCBI
|
|
3
|
Wong RJ, Cheung R and Ahmed A:
Nonalcoholic steatohepatitis is the most rapidly growing indication
for liver transplantation in patients with hepatocellular carcinoma
in the U.S. Hepatology. 59:2188–2195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Anstee QM, Reeves HL, Kotsiliti E, Govaere
O and Heikenwalder M: From NASH to HCC: Current concepts and future
challenges. Nat Rev Gastroenterol Hepatol. 16:411–428. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hartke J, Johnson M and Ghabril M: The
diagnosis and treatment of hepatocellular carcinoma. Semin Diagn
Pathol. 34:153–159. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Marshall HT and Djamgoz MBA:
Immuno-oncology: Emerging targets and combination therapies. Front
Oncol. 8:3152018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vinay DS, Ryan EP, Pawelec G, Talib WH,
Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HMCS, et
al: Immune evasion in cancer: Mechanistic basis and therapeutic
strategies. Semin Cancer Biol. 35(Suppl): S185–S198. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sharonov GV, Serebrovskaya EO, Yuzhakova
DV, Britanova OV and Chudakov DM: B cells, plasma cells and
antibody repertoires in the tumour microenvironment. Nat Rev
Immunol. 20:294–307. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Macdonald IK, Parsy-Kowalska CB and
Chapman CJ: Autoantibodies: Opportunities for early cancer
detection. Trends Cancer. 3:198–213. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kobayashi M, Katayama H, Fahrmann JF and
Hanash SM: Development of autoantibody signatures for common
cancers. Semin Immunol. 47:1013882020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
de Jonge H, Iamele L, Maggi M, Pessino G
and Scotti C: Anti-cancer auto-antibodies: Roles, applications and
open issues. Cancers (Basel). 13:8132021. View Article : Google Scholar :
|
|
13
|
Sexauer D, Gray E and Zaenker P:
Tumour-associated autoantibodies as prognostic cancer biomarkers-a
review. Autoimmun Rev. 21:1030412022. View Article : Google Scholar
|
|
14
|
Wouters MCA and Nelson BH: Prognostic
significance of tumor-infiltrating B cells and plasma cells in
human cancer. Clin Cancer Res. 24:6125–6135. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zheng M, Li YM, Liu ZY, Zhang X, Zhou Y,
Jiang JL, Zhu P, Yang XM, Tang J and Chen ZN: Prognostic landscape
of tumor-infiltrating T and B cells in human cancer. Front Immunol.
12:7313292022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Heo CK, Hwang HM, Lim WH, Lee HJ, Yoo JS,
Lim KJ and Cho EW: Cyclic peptide mimotopes for the detection of
serum Anti-ATIC autoantibody biomarker in hepato-cellular
carcinoma. Int J Mol Sci. 21:97182020. View Article : Google Scholar
|
|
17
|
Heo CK, Hwang HM, Lee HJ, Kwak SS, Yoo JS,
Yu DY, Lim KJ, Lee S and Cho EW: Serum anti-EIF3A autoantibody as a
potential diagnostic marker for hepatocellular carcinoma. Sci Rep.
9:110592019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hwang HM, Heo CK, Lee HJ, Kwak SS, Lim WH,
Yoo JS, Yu DY, Lim KJ, Kim JY and Cho EW: Identification of
anti-SF3B1 auto-antibody as a diagnostic marker in patients with
hepatocellular carcinoma. J Transl Med. 16:1772018. View Article : Google Scholar
|
|
19
|
Zhang XD, Wang Y and Ye LH: Hepatitis B
virus X protein accelerates the development of hepatoma. Cancer
Biol Med. 11:182–190. 2014.PubMed/NCBI
|
|
20
|
Hsieh A, Kim HS, Lim SO, Yu DY and Jung G:
Hepatitis B viral X protein interacts with tumor suppressor
adenomatous polyposis coli to activate Wnt/β-catenin signaling.
Cancer Lett. 300:162–172. 2011. View Article : Google Scholar
|
|
21
|
Yu DY, Moon HB, Son JK, Jeong S, Yu SL,
Yoon H, Han YM, Lee CS, Park JS, Lee CH, et al: Incidence of
hepatocellular carcinoma in transgenic mice expressing the
hepatitis B virus X-protein. J Hepatol. 31:123–132. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
National Library of Medicine (NIH): BRD2
bromodomain containing 2. NIH; Bethesda, MD: 2022, https://www.ncbi.nlm.nih.gov/gtr/genes/6046/. Updated
October 9, 2022.
|
|
23
|
Loganathan SN, Tang N, Fleming JT, Ma Y,
Guo Y, Borinstein SC, Chiang C and Wang J: BET bromodomain
inhibitors suppress EWS-FLI1-dependent transcription and the IGF1
autocrine mechanism in Ewing sarcoma. Oncotarget. 7:43504–43517.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun LY, Spong A, Swindell WR, Fang Y, Hill
C, Huber JA, Boehm JD, Westbrook R, Salvatori R and Bartke A:
Growth hormone-releasing hormone disruption extends lifespan and
regulates response to caloric restriction in mice. Elife.
2:e010982013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Belkina AC, Blanton WP, Nikolajczyk BS and
Denis GV: The double bromodomain protein Brd2 promotes B cell
expansion and mitogenesis. J Leukoc Biol. 95:451–460. 2014.
View Article : Google Scholar :
|
|
26
|
Pathak S, Stewart WCL, Burd CE, Hester ME
and Greenberg DA: Brd2 haploinsufficiency extends lifespan and
healthspan in C57B6/J mice. PLoS One. 15:e02349102020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hnilicova J, Hozeifi S, Stejskalova E,
Duskova E, Poser I, Humpolickova J, Hof M and Staněk D: The
C-terminal domain of Brd2 is important for chromatin interaction
and regulation of transcription and alternative splicing. Mol Biol
Cell. 24:3557–3568. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Suppiah A and Greenman J: Clinical utility
of anti-p53 auto-antibody: Systematic review and focus on
colorectal cancer. World J Gastroenterol. 19:4651–4670. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zaenker P, Gray ES and Ziman MR:
Autoantibody production in cancer-the humoral immune response
toward autologous antigens in cancer patients. Autoimmun Rev.
15:477–483. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kato T, Fahrmann JF, Hanash SM and
Vykoukal J: Extracellular vesicles mediate B cell immune response
and are a potential target for cancer therapy. Cells. 9:15182020.
View Article : Google Scholar :
|
|
31
|
Hao Q, Wu Y, Wu Y, Wang P and Vadgama JV:
Tumor-derived exosomes in tumor-induced immune suppression. Int J
Mol Sci. 23:14612022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Heo CK, Hwang HM, Ruem A, Yu DY, Lee JY,
Yoo JS, Kim IG, Yoo HS, Oh S, Ko JH and Cho EW: Identification of a
mimotope for circulating anti-cytokeratin 8/18 antibody and its
usage for the diagnosis of breast cancer. Int J Oncol. 42:65–74.
2013. View Article : Google Scholar :
|
|
33
|
Heo CK, Woo MK, Yu DY, Lee JY, Yoo JS, Yoo
HS, Ko JH, Kim JM, Choi JY, Kim IG, et al: Identification of
autoantibody against fatty acid synthase in hepatocellular
carcinoma mouse model and its application to diagnosis of HCC. Int
J Oncol. 36:1453–1459. 2010.PubMed/NCBI
|
|
34
|
Wang T and Zhang KH: New blood biomarkers
for the diagnosis of AFP-negative hepatocellular carcinoma. Front
Oncol. 10:13162020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li M, Jin C, Xu M, Zhou L, Li D and Yin Y:
Bifunctional enzyme ATIC promotes propagation of hepatocellular
carcinoma by regulating AMPK-mTOR-S6 K1 signaling. Cell Commun
Signal. 15:522017. View Article : Google Scholar
|
|
36
|
Che L, Pilo MG, Cigliano A, Latte G,
Simile MM, Ribback S, Dombrowski F, Evert M, Chen X and Calvisi DF:
Oncogene dependent requirement of fatty acid synthase in
hepatocellular carcinoma. Cell Cycle. 16:499–507. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen YR, Ouyang SS, Chen YL, Li P, Xu HW
and Zhu SL: BRD4/8/9 are prognostic biomarkers and associated with
immune infiltrates in hepatocellular carcinoma. Aging (Albany NY).
12:17541–17567. 2020. View Article : Google Scholar
|
|
38
|
Kudo M, Kitano M, Sakurai T and Nishida N:
general rules for the clinical and pathological study of primary
liver cancer, nationwide follow-up survey and clinical practice
guidelines: The outstanding achievements of the liver cancer study
group of Japan. Dig Dis. 33:765–770. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Korean Liver Cancer Study Group (KLCSG);
National Cancer Center, Korea (NCC): 2014.Korean liver cancer study
group-national cancer center Korea practice guideline for the
management of hepatocellular carcinoma. Korean J Radiol.
16:465–522. 2015.
|
